🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05435898
Starting soon Observational

Assessment and Digital-health Based Intervention on Subclinical Organ Damage and Cardiovascular Risk in Chinese

NCT05435898 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai 10th People's Hospital
Phase
Observational
Started
2022-10-01
Last updated
2022-06-28

Condition(s) studied

Cardiovascular DiseasesCardiovascular MorbiditySubclinical Organ DamageDigital Health

Study summary

To comprehensively evaluate subclinical organ damage of Chinese adults and its association with future cardiovascular disease and events.

To observe the significance of intervention based on digital health in preventing the onset and/or progression of subclinical organ damage and cardiovascular disease and events.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * aged 18 years or older * willing to participate the study and sign informed consent * available for long-term follow-up Exclusion Criteria: * severe heart disease (NYHA IV) * stage 4 or 5 CKD * malignant tumors or with life expectancy less than 5 years * stroke within 3 months * refuse to participate the study or not available for long-term follow up

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shanghai Tenth People's Hospital, Tongji University School of Medicine Shanghai Shanghai Municipality

More Shanghai 10th People's Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05435898 on ClinicalTrials.gov ↗ ← All trials in China